| Qlosi (U.S.N.L.M.) | |||
|---|---|---|---|
| Dosing (presbyopia) | 1 drop in each eye up to twice daily (2-3 hours apart) | ||
| Chem Specs | pilocarpine hydrochloride 0.4% | ||
| Quantities | Single use vial. 5 vials per pouch. Cartons of 30, 60 vials. | ||
| Cost | |||
| Class | cholinergic muscarinic agonist | ||
| Action | Pupil selective miotic. Cholinergic muscarinic (M3, G protein-coupled receptors) agonist. | ||
| Usage | Indicated for the treatment of presbyopia in adults. Maximum effect after a little more than an hour declining to near baseline after about 6 hours. |
||
| Warnings | Advise patients to not drive or operate machinery if vision is not clear. Warn patients about hazard of reduced vision with night driving or other situations involving reduced illumination. Rare cases of retinal detachment have been reported with miotics with detachment risk factors. Not recommended when iritis is present due to possible synechiae formation. May cause accommodative spasm |
||
| Contraindications | Hypersensitivity to active ingredient or excipients. | ||
| Pediatric use | n/a | ||
| Pregnancy | No adequate and well-controlled studies of QLOSI administration in pregnant women to inform a drug associated risk. Teratogenic when administration to rats at 1200 times the normal human ophthalmic dose. Still births increase when administered at 475 times the normal human dose. Decreased neonatal survival and reduced body weight of pups at 240 times the normal human dose. |
||
| Safety and effectiveness have not been established in patients over the age of 65. If taken with other eye drops allow 5 minutes between drops. |
|||